← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
ADCBiologicstaleDaiichi SankyoPhase 3

DS-1062a (DS-1062a)

Non-small Cell Lung Cancer · Metastatic Lung Cancer

#MetastaticLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 28상태 ACTIVE
ADCBiologicstaleAbbViePhase 3

MIRV (Mirvetuximab Soravtansine, Mirvetuximab Soravtansine (MIRV))

Epithelial Ovarian Cancer · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 28상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Oleclumab (Oleclumab)

Non-small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.5%임상시험 28상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Lung Neoplasm Malignant · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 28상태 RECRUITING
ADCBiologicstaleEMD Serono Research & Developme…Phase 2

Tepotinib (Tepotinib)

Non-small Cell Lung Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 54.7%임상시험 28상태 ACTIVE
ADCBiologicstaleAstellas Pharma IncPhase 2

ASG-22CE (ASG-22CE)

Bladder Cancer · Tumors

#Tumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 42.5%임상시험 27상태 ACTIVE
ADCBiologicstaleZhenzhen LiuPreclinical

Herombopag (Herombopag)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 27상태 RECRUITING
ADCBiologicstaleAlessandro SantinPhase 2

IMGN853 (IMGN853)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 27상태 RECRUITING
ADCBiologicstaleAbbViePhase 1

IMGN853 (Mirvetuximab Soravtansine, Mirvetuximab Soravtansine (IMGN853))

Breast Cancer Triple Negative · Breast Cancer Triple Negative

#BreastCancerTripleNegative#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 27상태 DISCONTINUED
ADCBiologicstaleAbbViePhase 3

Mirvetuximab soravtansine (Mirvetuximab soravtansine)

Endometrial Cancer; Endometrial Adenocarcinoma · Ovarian Cancer

#OvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 27상태 ACTIVE
ADCBiologicstaleAbbViePhase 2

MIRV; IMGN853 (mirvetuximab soravtansine, mirvetuximab soravtansine (MIRV; IMGN853))

Ovarian Cancer; Fallopian Tube · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 100%임상시험 27상태 RECRUITING
AntibodystaleZhiyong YuPhase 2

Inetetamab (Inetetamab)

Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 26상태 ACTIVE
ADCBiologicstaleGBG Forschungs GmbHPhase 2

Phesgo (Phesgo)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 50%임상시험 26상태 RECRUITING
ADCBiologicstaleBristol-Myers SquibbPhase 3

Amrubicin (Amrubicin)

Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 80%임상시험 25상태 RECRUITING
AntibodystaleRochePhase 2

CapeOX + bevacizumab (CapeOX + bevacizumab)

Unresectable Metastatic Colorectal Cancer; Microsatellite Stable (MSS) Colorectal Cancer (CRC) · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+4
임상시험 25상태 RECRUITING
ADCBiologicNational Cancer Institute (NCI)vedotin, and venetoclax dem…Phase 2

Larotrectinib (Larotrectinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 94.4%임상시험 25상태 RECRUITING
ADCBiologicstaleShanghai Hengrui Pharmaceutical…Phase 2

SHR-A2102 (SHR-A2102)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

ARV-471 (ARV-471)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 24상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

PLX3397 (PLX3397)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 24상태 RECRUITING

15 / 75 페이지

← 이전다음 →